-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $102

Benzinga·04/29/2026 13:19:07
Listen to the news
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $102.